Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304895 | 0.80 | ALDH1A1 (0.56) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL23801326 | 0.79 | HDAC8 (0.47) | PDE4BALDH1A1GAA | |
| SCHEMBL23802437 | 0.78 | CNR2 (0.47) | PDE4APDE4BPDE4CPDE4DACHE | |
| SCHEMBL25515699 | 0.75 | ALDH1A1 (0.65) | TP53SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL25521284 | 0.74 | PTPN5 (0.52) | ACHELMNAALDH1A1GAAPTPN5 | |
| SCHEMBL11400510 | 0.72 | TDP1 (0.52) | PDE4BACHEHTR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL8911428 | 0.71 | MAOA (0.49) | ACHEHTR4SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL23801792 | 0.70 | KMT2A (0.46) | PDE4APDE4BPDE4CPDE4DACHE | |
| SCHEMBL8910547 | 0.70 | MEN1 (0.48) | ACHEHTR4SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL23802440 | 0.69 | CNR2 (0.48) | PDE4APDE4BPDE4CPDE4DACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| WO-2021175855-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | OCIAD1, OCIAD2, OXER1 | PDE4A 2924/4885PDE4B 3046/4885PDE4C 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.